Windhover Information's 2006 Therapeutic Alliance Series: Cardiovascular Conference.

One Week Left to Presentation of Windhover's Top 10 Unlicensed Cardio Compounds

Nov. 15-16, 2006, Chicago, IL

NORWALK, Conn. -- In just over a week, an audience of influential investors, established cardiovascular companies and exciting new cardio technology companies will meet at Windhover Information's premier partnering and networking meeting, Therapeutic Alliances: Cardiovascular.

This event is a meeting point for business development and R&D focused strictly on cardiovascular technology, and will culminate in presentations from Windhover's highly-regarded Top 10 Unlicensed Cardio Projects.

TA: Cardiovascular, the most efficient partnering meeting this year for the cardiovascular industry, is slated for Nov. 15-16 in Chicago, immediately following the American Heart Association conference. Online registrations are still being accepted at www.cardioalliances.com.

Windhover presents the most promising new compounds for licensing

Windhover's Top 10 Licensable Cardiovascular Projects will present to an audience of senior executives and investors.

The Top 10 List is (in alphabetical order):

--  ARYx
    Compound: ATI-2042, a proprietary compound in Phase 2 development
    for the treatment of atrial fibrillation (AFIB). ARYx has
    engineered ATI-2042 with the goal of developing a therapy equally
    effective but safer than the "gold standard" treatment,
    amiodarone.

--  Cytokinetics
    Compound: CK-1827452, a novel, small-molecule, direct activator of
    cardiac myosin.

--  deCODE genetics
    Compound: DG 031, aimed at lowering risk of heart attack by
    inhibiting the activity of this pathway and reducing LTB4
    production.

--  Forbes Medi-Tech Inc.
    Compound: FM-VP4 (disodium ascorbyl phytosanyl phosphate), novel
    analogue of phytostanols which has demonstrated dramatic
    cholesterol-lowering and anti-atherosclerotic properties in
    pre-clinical trials. Study results showed that FM-VP4 was well
    tolerated and had significant LDL-lowering activity.

--  Isis Pharmaceutical
    Compound: ISIS 301012, a second-generation antisense inhibitor of
    apolipoprotein B-100 (ApoB), which has demonstrated potent,
    prolonged dose-dependant reduction of ApoB, cholesterol, low-
    density lipoprotein (LDL-C) and very low-density lipoprotein
    (VLDL) in Phase 1 trials. Triglyceride levels were also reduced.

--  Medicure Inc.
    Compound: MC 1, a potential treatment for blockages of blood to
    the heart (i.e. myocardial ischemia, associated with heart
    attacks, angina and arrhythmia) and the brain (i.e. ischemic
    stroke) and to prevent injury from ischemic reperfusion injury.

--  PeriCor Therapeutics
    Compound: Acadesine, which enhances endogenous adenosine-mediated
    cardioprotection and shown to improve post-MI survival; may reduce
    the incidence of perioperative ischemic complications and improve
    outcomes in coronary artery bypass surgery.

--  Proteo Biotech AG
    Compound: Elafin, a human protein that inhibits leukocyte elastase
    and proteinase 3. Elafin is produced in human skin, lungs and
    mammary gland naturally. Elafin seems to protect cells against
    destruction by the immune system. Inner organs, particularly
    muscles and vessels, do not contain Elafin, and therefore may be
    destroyed by the immune system more likely, if affected by an
    inflammation.

--  Surface Logix
    Compound: SLX 2101, an oral selective, fast-onset, long-acting
    (48 h) PDE-5 inhibitor designed specifically to expand the
    therapeutic potential of PDE-5 inhibition beyond erectile
    dysfunction into larger cardiovascular markets.

--  Viron Therapeutics Inc.
    Compound: VT 111, the first in a completely new class of
    therapeutic compounds for the treatment of inflammatory-based
    disorders. VT-111 will soon enter the clinic in its second
    indication, chronic organ rejection in transplant patients.

Presentations will include the product's target and first indication(s); other compounds addressing the same target; the relative advantage of the compound; the clinical results to date and general clinical plan for the future; IP on the compound or target; any partnerships currently held on the compound; and competitive advantage in the marketplace.

Additional information on these compounds is available here (http://www.cardioalliances.com/content/tb_schedule.aspx).

Cardio deals expert among leaders sharing insights

In addition to partnering and networking, attendees at TA: Cardiovascular will be able to benefit from workshops and sessions led by industry leaders. Windhover has just added a new workshop, Analyzing Cardiovascular Deals: Behind the Structures and Values of Key Recent Collaborations. Recent cardiovascular deals have ranged from relatively standard spec pharma arrangements to some of the highest-value alliances yet signed. This workshop will examine some of the representative recent transactions, examining why they were structured and valued as they were -- and how those lessons will apply to future cardiovascular deals.

The workshop will be led by Kenneth E. Weg, Founder and Chairman, Clearview Projects, Inc. Clearview Projects is a company dedicated to representing biopharmaceutical clients in strategic transactions to maximize the value of the technologies and products in their portfolios. He has over 33 years of experience in the pharmaceutical industry with Merck, Sharp & Dohme and Bristol-Myers Squibb. In 1993 he became president of Worldwide Medicines Group, Bristol-Myers Squibb Co., responsible for all ethical pharmaceuticals and over-the-counter medicines on a global basis.

Weg was elected to the Board of Directors and named as an Executive Vice President of Bristol-Myers Squibb Co. in May 1995. In May 1999, he was elected Vice Chairman of the board, retiring in February 2001. Currently, he serves on the Board of Directors of AVEO Pharmaceuticals, Inc., as Vice Chairman of the Board at Fox Chase Cancer Center, and as non-executive Chairman of the Board at Millennium Pharmaceuticals, Inc.

Other sessions on the agenda include:

* Best Practices in Cardiovascular Clinical Trials with Bruce N. Garrett, MD, Chief Medical Officer, Medifacts

* Heart of the Matter: Key Issues and Opportunities in the Cardiovascular Drug Space with Edward C. Saltzman, President, Defined Health

* Translating Cardiovascular Advances into Prescribed Drugs moderated by Edward C. Saltzman, President, Defined Health, and with Dr. Richard Pasternak, Vice President of Clinical Research in Cardiovascular/Atherosclerosis, Merck and Co.; and Robert A. D. Scott, MD, Executive Vice President of Research & Development and Chief Medical Officer, AtheroGenics.

* Trends, Valuations, and Success Rates in Cardiovascular Business Development: What Every Dealmaker Needs to Know with John Delyani, PhD, MBA, Director, Strategic Alliances Cardiovascular Diabetes & Metabolism, Novartis Institutes for Biomedical Research; and Ann C. Barry, PhD, Senior Director, Licensing and Development, Cardiovascular/Atherosclerosis, Pfizer, Inc.

* Workshop: Modeling your Market and Commercial Value for your Cardiovascular Drug

The complete schedule to date is available at http://www.cardioalliances.com.

Online pre-conference partnering available to registered attendees

Online partnering is now officially open. Registered attendees have access to Windhover's proprietary online, interactive partnering system, which enables participants to market their company and developments and engage in an ongoing dialogue with potential partners. Companies are therefore able to move quickly from identification of prospective partners to face-to-face meetings.

Companies from the US, Switzerland, South Korea, Finland, Denmark, Canada, the United Kingdom and Germany are among those on the attendee list. Among the major players planning to attend are Amgen, Boehringer Ingelheim, Genzyme Corp., Merck, Novartis, Orion Corp., Pfizer, The University of Pittsburgh and Wyeth.

A complete list of attending companies to date is available here (http://www.cardioalliances.com/content/tb_attendees.aspx)

To register, contact Alexandria Riley at [phone] ext. 113 or [e-mail]; or register on the TA Cardiovascular Alliances Conference 2006 website at www.cardioalliances.com.

About Windhover Information

Windhover Information Inc. has led the field in providing analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO, The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and audio conferences. For more on the company's products and services, please see www.windhover.com.